Durham startup Mycovia wins FDA approval for new antifungal drug
Durham-based Mycovia Pharmaceuticals has received its first product approval from the U.S. Food and Drug Administration. Here are the details.
Read More
Mycovia Pharmaceuticals
Mycovia Pharmaceuticals submits New Drug Application for oteseconazole
After three clinical trials, Mycovia has submitted its New Drug Application for a therapy that could help patients with recurrent vulvovaginal candidiasis, chronic yeast infection.
Read More
Mycovia to seek FDA approval for first antifungal drug
Antifungal developer Mycovia seeks FDA approval for its first drug, a treatment for yeast infections.
Read More
Durham’s Mycovia Pharma receives plenty of ‘buzz’ for global bio investor forum
Durham’s Mycovia Pharmaceuticals has emerged as the winner over nine finalist life science startups from across the nation vying for recognition in the “Buzz of BIO” Late Stage Leaders competition, part of the BIO Investor Forum taking place in San Francisco in October.
Read More
Mycovia drug shows promise against drug-resistant yeast infection
The developer of drugs in women’s health has shown that its oral drug candidate VT-1598 is active against Candida auris, an emerging multi-drug resistant fungal pathogen that presents a serious global health threat.
Read More
